Alentis Therapeutics

CompanySwitzerland

Alentis Therapeutics develops one asset. Mostly antibody acting on CLDN1; based in Switzerland.

1
Asset
Furthest stage
Not known
0
Trials
1
Signal

Pipeline

1
  • lixudebart

    Monoclonal antibody targeting Claudin-1

    Stage not known, Antibody, CLDN1

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1
  • Similar companies1

Intelligence